Page last updated: 2024-11-02

pioglitazone and Demyelinating Diseases

pioglitazone has been researched along with Demyelinating Diseases in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernardo, A1
Giammarco, ML1
De Nuccio, C1
Ajmone-Cat, MA1
Visentin, S1
De Simone, R1
Minghetti, L1
Duvanel, CB1
Honegger, P1
Pershadsingh, H1
Feinstein, D1
Matthieu, JM1

Other Studies

2 other studies available for pioglitazone and Demyelinating Diseases

ArticleYear
Docosahexaenoic acid promotes oligodendrocyte differentiation via PPAR-γ signalling and prevents tumor necrosis factor-α-dependent maturational arrest.
    Biochimica et biophysica acta. Molecular and cell biology of lipids, 2017, Volume: 1862, Issue:9

    Topics: Animals; Cell Differentiation; Cells, Cultured; Demyelinating Diseases; Docosahexaenoic Acids; Fatty

2017
Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro.
    Journal of neuroscience research, 2003, Jan-15, Volume: 71, Issue:2

    Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Astrocytes; Cells, Cultured; Complement Syste

2003